Market news

Vivos Therapeutics is implementing a restructuring plan targeting $3. 6 million in annual savings while expanding several revenue initiatives that management believes could support cash flow positivity by late 2026 or early 2027.

Company Continues to Make Significant Progress to Enhance Stockholders' Equity and Satisfy Nasdaq Listing RequirementsLITTLETON, Colo., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (Nasdaq: VVOS), a medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for patients with obstructive sleep apnea ("OSA") and other health conditions related to breathing and sleep disorders, today announced t

Detailed price information for Vivos Therapeutics Inc (VVOS-Q) from The Globe and Mail including charting and trades.

Physician-Aligned Collaboration to Support a Regional Sleep & Airway Medicine Center in Palm Beach CountyLITTLETON, Colo., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (Nasdaq: VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from obstructive sleep apnea ("OSA") and other health conditions related to breathing and sleep disorders, to

Average Weekly New Patient Referrals into Vivos’ Nevada Sleep & Airway Medicine Centers Rose 212% Over the Past Six Weeks from the Prior Six WeeksLITTLETON, Colo., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (Nasdaq: VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from obstructive sleep apnea (“OSA”) and other sleep disorders, t

Gainers Alector (NASDAQ:ALEC) shares increased by 9.7% to $2.59 during Tuesday's after-market session. The company's market cap stands at $256.8 million. NeuroSense Therapeutics (NASDAQ:NRSN) shares increased

New Location Expected to More Than Double Annual Revenue Production Capacity to Over $10 Million Official Grand Opening Slated for August 27 in Henderson, Nevada With Prominent Industry Opinion Leaders, Sleep Physicians, Dentists Among Scheduled Attendees LITTLETON, Colo., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (Nasdaq: VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and

Vivos Therapeutics Inc. (NASDAQ:VVOS) shares fell 6.

Moby summary of Vivos Therapeutics, Inc.'s Q2 2026 earnings call

Vivos Therapeutics (VVOS) delivered earnings and revenue surprises of +26.19% and -5.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Quarter highlighted by steadily increasing patient demand for Vivos’ differentiated array of highly effective OSA treatments Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from obstructive sleep apnea (

Call scheduled for today, Friday, August 14, 2026, at 5:00 pm ETLITTLETON, Colo., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from obstructive sleep apnea (“OSA”) and other sleep related breathing disorders, announced it plans to release its second quarter 2026 financial

The newly issued patent broadens intellectual property protection for Vivos’ flagship oral medical device platform, reinforcing its competitive position in the obstructive sleep apnea treatment market. Key Investor TakeawaysVivos Therapeutics (NASDAQ:VVOS) received a new U.

Continuation Patent Secures Broader, Design Independent Claims, Building on the Company's 2024 Foundational Patent for Its Vibrational Oral Appliance PlatformLITTLETON, Colo., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from obstructive sleep apnea (“OSA”) and other sleep

The latest update on Vivos Therapeutics centers on a trimmed fair value estimate, with the price target moving from about US$2.45 to roughly US$2.12 per share. This shift lines up with recent Street commentary that has paired cautious or Neutral ratings with lower targets, as analysts weigh balance sheet concerns and potential equity dilution against ongoing clinical and commercial efforts. Read on to see what is driving these price target resets and how to track the evolving narrative around...

The latest analyst update on Vivos Therapeutics cuts the fair value estimate from US$5.83 to US$2.45, a shift that directly lowers the implied price target in current models. Analysts link this move to refreshed assumptions around discount rates and revenue growth, describing the reduced target as a recalibration of expectations rather than a reaction to a single issue. As you read on, you will see how this new price target fits into the evolving narrative around Vivos Therapeutics and what...